^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | lapatinib (EGFR inhibitor, HER2 inhibitor) + pelcitoclax (APG-1252) (Bcl2 inhibitor, Bcl-xL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
6140 / 2 - Caspase-3 mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer
Published date:
03/15/2023
Excerpt:
Finally, in the HER2-positive GC cells xenotransplantation models, both lapatinib and APG-1252 monotherapy could delay tumor growth, while the combination therapy significantly suppressed tumor growth….Taken together, our data indicated that anti-HER2 agents could upregulate the expression of GSDME, and the combination of lapatinib and APG-1252 showed a synergistic antitumor effect against HER2-positive gastric cancer...
Source:
Title:
Abstract 74: Co-targeting BCL-xL and HER2 high expression to overcome apoptosis blockade in gastric cancer
Published date:
05/15/2020
Excerpt:
...in mouse tumor models derived from HER2+ gastric cancer cell line NCI-N87 or patient-derived xenografts (PDXs), combined treatment with AGP-1252 and HER2 inhibitor lapatinib synergistically inhibited tumor growth, suggesting that lapatinib may be able to increase mitochondrial priming, thus sensitizing cancer cells to APG-1252.
DOI:
10.1158/1538-7445.AM2020-74
